← Back to Search

Aminoglycoside Antibiotic

Gentamicin for Junctional Epidermolysis Bullosa

Phase 1 & 2
Recruiting
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. JEB patients with nonsense mutations in the LAMB3 gene in either one or two alleles.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial will test if gentamicin can be used to treat Herlitz junctional epidermolysis bullosa (H-JEB), an incurable skin disease, by restoring laminin 332 assembly and improving wound closure.

Eligible Conditions
  • Epidermolysis Bullosa

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Generation of new hemidesmosomes as assessed by electron microscopy.
Incidence of Treatment-Emergent Adverse Events
Increased laminin beta 3 / laminin 332 expression as assessed by immunofluorescence.
Secondary study objectives
Improved wound closure.
Reduction in blistering

Side effects data

From 2023 Phase 2 & 3 trial • 23 Patients • NCT03503513
63%
Urinary Tract Infection
21%
COVID-19
16%
flu-like symptoms
16%
bladder spasms
11%
Clinically significant labs
11%
GI upset
11%
abdominal stoma issue
11%
heel wound
5%
bowel obstruction
5%
Serratia tissue infection
5%
loose stool
5%
hematuria
5%
inguinal pain
5%
parotitis
5%
vaginitis
5%
muscle strain
5%
Gross hematuria
5%
bladder stone
5%
bone infection
5%
bleeding from catheter site
5%
bladder irritation
5%
conjunctivitis
5%
sweating
5%
pulmonary embolism
5%
Post-COVID 19 pneumonia
5%
cystolitholapaxy
5%
Renal stone removal
5%
air in bladder
5%
upper respiratory infection
5%
pneumonia
5%
nasal discharge
5%
urinary discharge
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gentamicin Sulfate

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Gentamicin SulfateExperimental Treatment1 Intervention
IV Arm: 7.5 mg/kg gentamicin once daily for 14 days. Topical Arm: 0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gentamicin
FDA approved

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
946 Previous Clinical Trials
1,604,832 Total Patients Enrolled
4 Trials studying Epidermolysis Bullosa
26 Patients Enrolled for Epidermolysis Bullosa
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top